Table 2_Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.xlsx

Background<p>Immune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need.</p>Methods<p>We conducted a prospect...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Elena Poddubskaya (5725829) (author)
مؤلفون آخرون:	Maria Suntsova (4379872) (author), Marina Lyadova (20417093) (author), Daniil Luppov (20417096) (author), Anastasia Guryanova (20417099) (author), Vladimir Lyadov (17847073) (author), Andrew Garazha (4379866) (author), Maksim Sorokin (7880480) (author), Anna Semenova (16858820) (author), Vitaly Shatalov (20417102) (author), Maria Biakhova (20417108) (author), Alexander Simonov (6206033) (author), Aleksey Moisseev (18618205) (author), Anton Buzdin (2819995) (author)
منشور في:	2024
الموضوعات:	Genetic Immunology immune checkpoint therapy pembrolizumab ipilimumab nivolumab non-small cell lung cancer RNA sequencing gene expression biomarker personalized medicine
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Table 2_Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.xlsx

مواد مشابهة